Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10016024HBVENSG00000077498.9protein_codingTYRNoNo7299L8B082
P14679
TVIS10026684HBVENSG00000077498.9protein_codingTYRNoNo7299L8B082
P14679
TVIS10046898HBVENSG00000077498.9protein_codingTYRNoNo7299L8B082
P14679
TVIS20040130HPVENSG00000077498.9protein_codingTYRNoNo7299L8B082
P14679
TVIS20068786HPVENSG00000077498.9protein_codingTYRNoNo7299L8B082
P14679
TVIS44032379HTLV-1ENSG00000077498.9protein_codingTYRNoNo7299L8B082
P14679
TCGA Plot Options
Drug Information
GeneTYR
DrugBank IDDB00548
Drug NameAzelaic acid
Target IDBE0000252
UniProt IDP14679
Regulation Typeinhibitor
PubMed IDs2114832; 2963038; 4004885; 448162
CitationsSchallreuter KU, Wood JW: A possible mechanism of action for azelaic acid in the human epidermis. Arch Dermatol Res. 1990;282(3):168-71.@@Nazzaro-Porro M: Azelaic acid. J Am Acad Dermatol. 1987 Dec;17(6):1033-41.@@Picardo M, Passi S, Sirianni MC, Fiorilli M, Russo GD, Cortesi E, Barile G, Breathnach AS, Nazzaro-Porro M: Activity of azelaic acid on cultures of lymphoma- and leukemia-derived cell lines, normal resting and stimulated lymphocytes and 3T3 fibroblasts. Biochem Pharmacol. 1985 May 15;34(10):1653-8.@@Nazzaro-Porro M, Passi S, Balus L, Breathnach A, Martin B, Morpurgo G: Effect of dicarboxylic acids on lentigo maligna. J Invest Dermatol. 1979 Jun;72(6):296-305.
GroupsApproved
Direct ClassificationMedium-chain fatty acids
SMILESOC(=O)CCCCCCCC(O)=O
Pathways
PharmGKBPA164754850
ChEMBLCHEMBL1238